Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
106
resultados
Última actualización
27/06/2026 [07:08:00]
Resumen de: CN120992924A
The invention belongs to the technical field of Ultrap1 enzyme quantitative detection, and particularly relates to an Ultrap1 enzyme double-antibody sandwich ELISA (enzyme-linked immuno sorbent assay) kit and application. Comprising an elisa plate coated with an anti-Ultrap1 enzyme mouse monoclonal antibody, an anti-Ultrap1 enzyme rabbit polyclonal antibody, an HRP-labeled goat anti-rabbit antibody, a diluent, a cleaning solution, a confining solution, a developing solution and a stop solution. According to the present invention, the complex of the Ulp1 enzyme and the SUMO tag protein is adopted as the immunogen to simultaneously immunize mice and New Zealand rabbits so as to prepare different species of the good affinity Ulp1 enzyme antibodies, and then the optimal reaction condition is further screened to develop the stable double-antibody sandwich ELISA detection kit with characteristics of high specificity and strong sensitivity, the defects in the prior art can be effectively overcome.
Resumen de: EP4279503A1
0001 Provided is a method that enables the presence and/or amount of bacteria of Enterobacteriaceae in a food/drink sample, an environmental sample, or a biological sample to be detected easily and efficiently in a short amount of time. Said method includes a step for simultaneously detecting, on the basis of an antigen-antibody reaction, the presence and/or amount of bacteria of Enterobacteriaceae of at least two different genera in a sample.
Resumen de: CN122214226A
本发明公开了一种htrA基因敲除的减毒沙门氏菌重组工程菌株及其应用，对减毒沙门氏菌VNP20009进行基因组遗传改造，将基因组中的htrA基因敲除，获得ΔhtrA‑VNP菌株。通过回补性表达带有/不带有信号肽的HtrA蛋白，首次证实信号肽对于HtrA蛋白的功能发挥至关重要。无信号肽的htrA基因回补菌株与ΔhtrA‑VNP菌株生物学表型无显著差异。本发明所述的表达带有信号肽的HtrA蛋白的ΔhtrA‑VNP菌株，HtrA蛋白通过调控细菌胞外多糖水平，一方面影响菌株的免疫原性与抗癌效果，另一方面影响菌株对抗巨噬细胞的杀伤效果，进而影响细菌在体内的分布特性。本发明基于htrA基因活性作用模式，建立了瘤内时空特异性启动表达带有信号肽的HtrA蛋白的ΔhtrA‑VNP菌株，实现更高效、安全与精准的活体微生物抗肿瘤治疗。
Resumen de: CN122182751A
本发明公开了一种细菌复合疫苗与顺铂的协同抗肿瘤组合及其应用，属于肿瘤药物制备技术领域。所述抗肿瘤组合包括以下成份：细菌复合疫苗和顺铂。本发明通过细菌复合疫苗和顺铂的协同配合，在对肿瘤模型的试验小鼠进行治疗时发现，相较于单一的细菌复合疫苗治疗组和单一的顺铂治疗组，二者的协同用药对肿瘤细胞增殖的抑制作用显著上升，具有良好的抗肿瘤效果。
Resumen de: AU2024374864A1
Cyclic dinucleotides, which are a type of signaling substance for cancer treatment, are secondary messengers of intracellular events initiated by GPCR activation and act as a stimulator of interferon genes (STING), and thus can have a significant effect on tumor suppression. Meanwhile, when cancer occurs in a subject, angiogenesis and cell growth proceed at a very high rate in the body, and thus an oxygen-deficient environment is created due to incomplete angiogenesis in cancer tissues, which may be very suitable for the proliferation of anaerobic bacteria such as Salmonella sp. strains or E. coli. Therefore, the present invention relates to a DNA construct into which is introduced a gene for an enzyme that synthesizes a signaling substance for cancer treatment, e.g., a cyclic dinucleotide, or to a strain transformed with a vector comprising the DNA construct. The DNA construct or the strain transformed with a vector comprising the DNA construct, according to the present invention, targets cancer in a subject and then secretes C-di-AMP or C-di-GMP synthase in the surrounding environment of the cancer, and thus can very effectively prevent or treat cancer and, at the same time, can diagnose cancer in real time.
Resumen de: US20260158079A1
Provided herein are compositions comprising substantially non-viable Gram-negative bacterial organisms that have a substantial reduction in endotoxin activity and/or pyrogenicity and methods for treating a cancer using the same. Also provided are methods for treating cancer provided herein, comprising administering to a mammal diagnosed with cancer, substantially non-viable Gram-negative bacteria having a substantial reduction in endotoxin activity and/or pyrogenicity, in an amount sufficient to inhibit growth or metastasis of the cancer. An additional method is provided comprising administering viable or non-viable Gram-negative bacterial organisms that have a genetic defect that results in a substantial loss of lipopolysaccharide within the outer membrane of the bacteria. Further provided are methods for reducing endotoxin activity and/or pyrogenicity in Gram-negative bacteria comprising treatment with polymyxin and glutaraldehyde.
Resumen de: KR20260084896A
본 발명은 콜레라균 또는 장티푸스균에 특이적인 단일클론 항체 및 이를 이용한 콜레라와 장티푸스 동시 신속진단키트에 관한 것으로, 보다 상세하게는 서열번호 2, 서열번호 4, 서열번호 6 또는 서열번호 8의 아미노산 서열로 표시되는 중쇄 가변영역을 포함하는 콜레라균(Vibrio cholerae)에 특이적으로 결합하는 단일클론 항체 및 서열번호 10 또는 서열번호 12의 아미노산 서열로 표시되는 중쇄 가변영역을 포함하는 살모넬라 티피(Salmonella typhi)에 특이적으로 결합하는 단일클론 항체를 이용한 콜레라와 장티푸스 동시 신속진단키트에 관한 것이다.
Resumen de: AU2026203814A1
The present disclosure relates generally to compositions, dosage forms, and methods for preventing and treating infections. The compositions include intact and substantially non- viable Gram-negative bacterial cells which have been treated to reduce lipopolysaccharide (LPS)-associated endotoxin activity, which surprisingly have increased activity to trigger immune cell production of cytokines. ay a y
Resumen de: MX2026005882A
Disclosed herein are methods and systems for rapid detection of microorganisms such as Listeria spp. in a sample. A genetically modified bacteriophage is also disclosed which comprises an indicator gene in the late gene region. The specificity of the bacteriophage, such as Listeria-specific bacteriophage, allows detection of a specific microorganism, such as Listeria spp. and an indicator signal may be amplified to optimize assay sensitivity.
Resumen de: WO2026108702A1
Disclosed in the present invention are a nanobody for detecting Escherichia coli O157:H7 and a preparation method therefor. The present invention aims to provide a nanobody for detecting Escherichia coli O157:H7 with high detection accuracy and a simple acquisition method. The amino acid sequence of the nanobody is set forth in SEQ ID NOs. 1-3. The present invention belongs to the technical field of biopharmaceuticals.
Resumen de: US20260144857A1
Technologies for the prevention and/or treatment of Shigella infections.
Resumen de: US20260146994A1
A system and method for detecting, enumerating, or extracting microorganisms in a sample is disclosed. Target microorganisms, such as Salmonella bacteria, may be of interest. Magnetic beads may be bound to the target microorganisms. After which, the bead-bound cells may be isolated. For example, a magnetic field may be applied in order to separate the target cells (with the magnetic beads attached thereto) and move then to a predetermined section of the well. Agar, or other immobilizing agent, may be added to the wells in order to immobilize the target cells. After which, the target cells are incubated and periodically analyzed to determine whether the target cells are growing, thereby indicating that the microorganisms are contained within the well.
Resumen de: WO2025021695A1
The present invention relates to immunogenic compositions comprising outer membrane vesicles (OMVs) adsorbed to an aluminium hydroxide adjuvant, whereby the aluminium hydroxide adjuvant is quenched. The present invention also relates to the use of the immunogenic compositions for providing protection against diseases caused by Gram-negative bacteria. The present invention also relates to a method for reducing particle aggregation and/or average particle diameter in compositions comprising OMVs and an aluminium hydroxide adjuvant.
Resumen de: WO2025021710A1
The present invention relates to immunogenic compositions comprising S. enterica serovar Paratyphi A outer membrane vesicles (OMVs), vaccines comprising the immunogenic compositions and methods and uses of the immunogenic compositions. The present invention also relates to an S. Paratyphi A bacterium comprising modified lipid A.
Resumen de: CN122081185A
本发明属于生物医药技术领域，公开了一种用于肿瘤原位表达微管抑制蛋白的工程化细菌及其应用。通过将微管抑制蛋白基因构建至表达载体，最终转入细菌，形成工程菌。该工程菌能靶向定植于肿瘤微环境，表达微管抑制蛋白，有效抑制肿瘤细胞，显著抑制实体瘤生长，且安全性优良。
Resumen de: CN122081186A
本发明公开了一种三级淋巴结构生物模型的构建方法，可以快速高效诱导原位TLS的产生，不依赖于特定的组织器官，不需要细胞编辑、转基因小鼠等复杂昂贵的制备流程，在2～3周内产生稳定、成熟、存续时间长的TLS结构，具有周期短、成本低、操作简单、可重复、安全有效的特点。
Resumen de: CN118846069A
The invention relates to the field of medicine, in particular to a pharmaceutical composition and a preparation method and application thereof.The pharmaceutical composition comprises a first effective component, a second effective component and a pharmaceutically acceptable carrier or auxiliary material, the microbial agent comprises any one or more of staphylococcus aureus, bordetella pertussis, diphtheria toxoid, tetanus toxoid, typhoid bacillus or paratyphoid bacillus, and the second effective component comprises polyinosinic acid, polycytidylic acid and vitamin. The pharmaceutical composition belongs to artificial active immunotherapy aiming at tumors, can'stimulate 'the whole immune system, enables the therapy of activating the human immune system by bacteria to kill cancer cells to be quite stable and reliable, can remarkably save and prolong the life of cancer patients, has extremely high safety and extremely small toxic and side effects, and is suitable for clinical application. And the preparation cost is low.
Resumen de: US20260137738A1
The present invention relates to a novel bacteriophage OPT-SALO1 with specific killing ability for Salmonella enterica, an antibiotic composition comprising the bacteriophage, a composition for adding to a feed, a feed, a disinfectant or a cleaning agent, and a method for preventing or treating infectious diseases caused by Salmonella enterica comprising a step of administering the bacteriophage to a subject.
Resumen de: US20260140114A1
The disclosure provides methods, compositions, and kits for enhanced detection of microbes in samples and monitoring of antimicrobial activity in a subject.
Resumen de: AU2026203336A1
Outer membrane vesicles from bacteria of the Burkholderia pseudomallei complex can be used as adjuvants in compositions and methods to potentiate the immune response to immunogens. ay a y
Resumen de: US20260137765A1
A method of producing a monomer of a Shiga toxin B-subunit (STxB) protein or of a variant thereof by peptide chemical synthesis, as well as to a method of producing a pentamer of the STxB protein or of the variant thereof. The methods are particularly advantageous as they overcome major issues typically observed in peptide chemical synthesis, including solubility and purity issues.
Resumen de: AU2026203393A1
DETOXIFIED LIPOPOLYSACCHARIDES (LPS), NATURALLY NON-TOXIC LPS, AND USES THEREOF The invention relates to an enriched population of modified lipopolysaccharide (LPS) molecular species being: - devoid of phosphate group at position C1 of the reducing end of their lipid A domain; and - substituted at position C6’ of the non-reducing end of their lipid A domain by a 10 hydrophilic moiety, with the proviso that said hydrophilic moiety is not a hydroxyl group. It also relates to compositions comprising the enriched population of modified LPS; and uses of naturally-occurring LPS molecular species and/or enriched population of modified LPS molecular species for treating and/or preventing cancer, inflammatory 15 diseases or infectious diseases, and for stimulating an immune response or vaccinating a subject. - 10 - ay a y - - 1
Resumen de: US20260139012A1
A method for increasing the presentation of ETEC CS6 antigen on a cell surface, comprising the step of contacting cells expressing said antigen with an aqueous solution comprising 0.6-2.2 percent phenol by weight, such that the presentation of said antigen is increased by at least 100%. A method for the manufacture of a killed whole cell vaccine for immunization against CS6-expressing ETEC. Cells and vaccines obtainable by the above methods.
Resumen de: WO2026102349A1
Interleukin-23 receptor (IL23R) VHH antibodies are disclosed, as well as methods of making and using the same, e.g., for treatment of IL23-mediated diseases and disorders, including, e.g., gastrointestinal-related (Gl-related) diseases (e.g., inflammatory bowel disease (IBD) (e.g., ulcerative colitis (UC) or Crohn's disease (CD)), a colon cancer, a small intestine cancer, a gastric cancer, an irritable bowel syndrome, a gastrointestinal ulcer, a gut-associated infection (e.g., a Salmonella infection or a Clostridium difficile infection), celiac disease, or pathogenic inflammation).
Nº publicación: WO2026098490A1 15/05/2026
Solicitante:
INNER MONGOLIA EPPEN BIOTECH CO LTD [CN]
\u5185\u8499\u53E4\u4F0A\u54C1\u751F\u7269\u79D1\u6280\u6709\u9650\u516C\u53F8
Resumen de: WO2026098490A1
Disclosed in the present application is the use of Salmonella typhimurium-derived glutamate dehydrogenase and related biomaterials thereof in amino acid synthesis. Provided in the present application is the use of Salmonella typhimurium-derived glutamate dehydrogenase for improving the L-amino acid yield of a microorganism. In the present application, an optimized coding gene of the Salmonella typhimurium-derived glutamate dehydrogenase is further obtained by means of codon optimization, and the introduction of the optimized coding gene into a recipient microorganism can significantly improve the L-amino acid yield of the recipient microorganism.
BOPI
Sede Electrónica
